What is XOMA Royalty Corporation's earnings per share (EPS)?

XOMA Royalty Corporation (XOMA) reported diluted earnings per share of $1.46 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

XOMA Royalty Corporation (XOMA) Financials

XOMA

Trailing 12 months to March 31, 2026

Revenue $48.6M +13.2% YoY

Net Income $33.8M +1282.6% YoY

EPS (Diluted) $1.57 +237.7% YoY

Operating Cash Flow $6.8M +202.9% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XOMA SEC filings page.

XOMA Royalty Corporation (XOMA) reported $48.6M in revenue over the twelve months to Mar 31, 2026, up 13.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI XOMA FY2025 2026-10-03

2025 restored reported profitability, but cash generation remained modest while liabilities continued financing much of the asset base.

FY2025 net income reached $31.7M, yet operating cash flow was only $2.9M, so the earnings rebound was not matched by comparable cash generation. In FY2024, the net loss of $13.8M broadly matched operating cash flow of -$13.7M, making the latest divergence an important change in earnings quality.

Total assets expanded to $272.7M while total liabilities reached $168.7M in FY2025, indicating that the larger asset base was financed substantially through obligations rather than accumulated equity alone. Debt-to-equity nevertheless fell to 1.1x from 1.7x, reflecting some improvement in balance-sheet leverage.

A $50.9M investing cash inflow outweighed a $26.5M financing outflow in FY2025, showing that reported cash movement was driven more by investing activity and financing decisions than by operating cash generation. This makes the business's cash profile materially different from one funded primarily by recurring operations.

Financial Health Signals

Financial Health Score 67/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of XOMA Royalty Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

XOMA Royalty Corporation held $82.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $2.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and XOMA Royalty Corporation scores 86/100 among other emerging companies.

Dilution

XOMA Royalty Corporation had 12M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and XOMA Royalty Corporation scores 68/100 among other emerging companies.

R&D Intensity

XOMA Royalty Corporation spent $1.7M on research and development in fiscal year 2025, which was 4.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and XOMA Royalty Corporation scores 21/100 among other emerging companies.

Revenue Progress

XOMA Royalty Corporation reported revenue of $52.1M in fiscal year 2025, against $28.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and XOMA Royalty Corporation scores 93/100 among other emerging companies.

Burn Trend

XOMA Royalty Corporation's operations generated $2.9M of cash in fiscal year 2025, against $13.7M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and XOMA Royalty Corporation scores 89/100 among other emerging companies.

Balance Sheet

XOMA Royalty Corporation's cash, cash equivalents and investments came to $82.9M at the end of fiscal year 2025, against $168.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and XOMA Royalty Corporation scores 43/100 among other emerging companies.

Altman Z-Score Distress

-3.05

XOMA Royalty Corporation scores -3.05, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($710.2M) relative to total liabilities ($168.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

XOMA Royalty Corporation passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.09x

For every $1 of reported earnings, XOMA Royalty Corporation generates $0.09 in operating cash flow ($2.9M OCF vs $31.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

0.87x

XOMA Royalty Corporation earns $0.87 in operating income for every $1 of interest expense ($11.4M vs $13.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$12.3M

YoY-22.6%

QoQ-10.5%

5Y CAGR+101.0%

10Y CAGR+12.0%

XOMA Royalty Corporation generated $12.3M in revenue in Q1 2026. This represents a decrease of 22.6% from the same quarter a year earlier. Against the prior quarter it is down 10.5%.

Net Income

$4.5M

YoY+88.6%

QoQ-26.8%

XOMA Royalty Corporation reported $4.5M in net income in Q1 2026. This represents an increase of 88.6% from the same quarter a year earlier. Against the prior quarter it is down 26.8%.

EPS (Diluted)

$0.17

QoQ-34.6%

XOMA Royalty Corporation earned $0.17 per diluted share (EPS) in Q1 2026. Against the prior quarter it is down 34.6%.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$85.6M

YoY-5.2%

QoQ+3.2%

5Y CAGR+4.1%

10Y CAGR+6.4%

XOMA Royalty Corporation held $85.6M in cash against $88.8M in long-term debt as of Q1 2026.

Shares Outstanding

13M

QoQ+5.3%

5Y CAGR+2.2%

10Y CAGR-20.2%

XOMA Royalty Corporation had 13M shares outstanding in Q1 2026. Against the prior quarter it is up 5.3%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Operating Margin

-3.9%

YoY-41.2pp

QoQ-19.8pp

XOMA Royalty Corporation's operating margin was -3.9% in Q1 2026, reflecting core business profitability. This is down 41.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 19.8 percentage points.

Net Margin

36.3%

YoY+21.4pp

QoQ-8.1pp

XOMA Royalty Corporation's net profit margin was 36.3% in Q1 2026, showing the share of revenue converted to profit. This is up 21.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.1 percentage points.

Return on Equity

4.8%

YoY+2.0pp

QoQ-2.5pp

5Y change+13.8pp

XOMA Royalty Corporation's ROE was 4.8% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.

Gross Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$49K

YoY-96.2%

QoQ-82.6%

5Y CAGR-4.3%

XOMA Royalty Corporation invested $49K in research and development in Q1 2026. This represents a decrease of 96.2% from the same quarter a year earlier. Against the prior quarter it is down 82.6%.

Share Buybacks

$264K

YoY-51.6%

QoQ-98.1%

XOMA Royalty Corporation spent $264K on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 51.6% from the same quarter a year earlier. Against the prior quarter it is down 98.1%.

Capital Expenditures

Not reported for Q1 2026.

XOMA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

XOMA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$48.6M	$52.1M+83.1%	$28.5M+498.7%	$4.8M-21.1%	$6.0M-84.2%	$38.2M+29.9%	$29.4M+60.0%	$18.4M+246.7%	$5.3M-89.9%	$52.7M+847.0%	$5.6M-90.0%	$55.4M+193.9%	$18.9M-46.8%	$35.5M+4.9%	$33.8M-42.0%	$58.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$143K	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$33.6M-42.2%	$58.2M
R&D Expenses	$468K	$1.7M-40.5%	$2.9M+1910.5%	$143K-6.5%	$153K-10.5%	$171K+0.6%	$170K-86.4%	$1.3M-25.5%	$1.7M-78.6%	$7.9M-82.2%	$44.2M-37.6%	$70.9M-12.3%	$80.7M+7.9%	$74.9M+9.3%	$68.5M+0.5%	$68.1M
SG&A Expenses	$39.8M	$36.1M+4.7%	$34.5M+34.6%	$25.6M+10.4%	$23.2M+13.3%	$20.5M+21.8%	$16.8M-20.0%	$21.0M+13.1%	$18.6M-23.7%	$24.3M+32.8%	$18.3M-11.1%	$20.6M+3.8%	$19.9M+7.5%	$18.5M+9.6%	$16.9M-29.8%	$24.0M
Operating Income	$5.0M	$11.4M+128.5%	-$40.0M+4.5%	-$41.8M-140.3%	-$17.4M-199.3%	$17.5M+41.2%	$12.4M+419.6%	-$3.9M+77.0%	-$16.9M-199.0%	$17.0M+127.7%	-$61.6M-55.0%	-$39.7M+51.5%	-$81.8M-40.6%	-$58.2M-2.8%	-$56.6M-66.8%	-$34.0M
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	$12.4M+422.2%	-$3.9M+77.1%	-$16.8M-197.1%	$17.3M+128.5%	-$60.8M-59.0%	-$38.2M+52.2%	-$79.9M-44.5%	-$55.3M-5.3%	-$52.5M-83.7%	-$28.6M
Interest Expense	$12.9M	$13.0M-5.8%	$13.8M+2332.3%	$569K	N/A	$461K-75.0%	$1.8M-3.9%	$1.9M+108.1%	$922K-25.5%	$1.2M-68.6%	$3.9M+4.8%	$3.8M-12.5%	$4.3M-7.1%	$4.6M+5.6%	$4.4M+78.2%	$2.5M
Income Tax	N/A	$103K+101.8%	-$5.7M	$0+100.0%	-$15K-116.5%	$91K+106.1%	-$1.5M	$0+100.0%	-$98K-105.9%	$1.7M	$0	$0	$0+100.0%	-$14K+81.1%	-$74K-593.3%	$15K
Net Income	$33.8M	$31.7M+329.4%	-$13.8M+66.2%	-$40.8M-138.7%	-$17.1M-208.3%	$15.8M+18.8%	$13.3M+770.9%	-$2.0M+85.1%	-$13.3M-191.4%	$14.6M+127.3%	-$53.5M-159.8%	-$20.6M+46.2%	-$38.3M+69.1%	-$124.1M-74.6%	-$71.1M-117.0%	-$32.7M
EPS (Basic)	N/A	$1.53+192.7%	-$1.65+59.2%	-$4.04-104.0%	-$1.98-387.0%	$0.69-15.9%	$0.82+456.5%	-$0.23+85.5%	-$1.59-312.0%	$0.75+108.4%	-$8.89-154.0%	-$3.50+50.9%	-$7.13-398.6%	-$1.43-30.0%	-$1.10	N/A
EPS (Diluted)	$1.57	$1.46	-$1.65+59.2%	-$4.04-104.0%	-$1.98	$0.65-16.7%	$0.78	-$0.23+85.5%	-$1.59	$0.73	-$8.89-154.0%	-$3.50	-$13.49	-$1.43-30.0%	-$1.10	N/A
Diluted Shares (Avg)	N/A	18M	12M+2.0%	11M+100408.2%	11,413	12M+6.0%	12M	9M+4.7%	8M	8M	6M+2.2%	6M	6M	87M+34.5%	65M+204486.9%	31,590

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$12.3M-22.6%	$13.8M+57.9%	$9.4M+29.9%	$13.1M+18.4%	$15.9M+967.9%	$8.7M+375.4%	$7.2M+767.1%	$11.1M+568.6%
R&D Expenses	$49K-96.2%	$281K-67.5%	$69K-91.6%	$69K-94.1%	$1.3M+3818.2%	$864K+3356.0%	$817K+3168.0%	$1.2M+2876.9%
SG&A Expenses	$11.9M+45.6%	$10.4M+48.9%	$9.7M+21.4%	$7.8M-29.1%	$8.1M-3.7%	$7.0M-3.7%	$8.0M+25.9%	$11.0M+90.5%
Operating Income	-$480K-108.1%	$2.2M+130.1%	-$1.3M+91.5%	$4.6M+145.7%	$5.9M+184.7%	-$7.3M+63.6%	-$15.6M-170.3%	-$10.1M-69.2%
Interest Expense	$3.4M-3.1%	$3.0M-10.8%	$3.3M-5.5%	$3.2M-4.9%	$3.5M-2.4%	$3.4M	$3.5M	$3.4M
Income Tax	$1K	N/A	$49K	N/A	$0	-$5.7M	$0	$0
Net Income	$4.5M+88.6%	$6.1M+253.8%	$14.1M+181.5%	$9.2M-42.5%	$2.4M+127.5%	-$4.0M+80.3%	-$17.2M-213.0%	$16.0M+396.0%
EPS (Basic)	$0.18+200.0%	$0.27+160.0%	$0.74+146.5%	$0.46-47.7%	$0.06+107.0%	-$0.45+75.9%	-$1.59-165.0%	$0.88+249.2%
EPS (Diluted)	$0.17	$0.26	$0.70	$0.44-47.6%	$0.06	-$0.45+75.9%	-$1.59-165.0%	$0.84
Diluted Shares (Avg)	17M	N/A	18M	18M+2.5%	18M	N/A	12M+2.1%	17M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA.

XOMA Balance Sheet

XOMA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$272.7M+23.2%	$221.3M-5.6%	$234.3M+66.9%	$140.4M-15.7%	$166.6M+32.9%	$125.3M+30.9%	$95.7M+50.1%	$63.8M+41.9%	$44.9M+56.7%	$28.7M-61.7%	$74.9M-16.2%	$89.4M-33.7%	$134.8M+27.5%	$105.7M+35.4%	$78.0M
Current Assets	$117.3M-6.6%	$125.6M-25.8%	$169.3M+176.4%	$61.3M-36.8%	$97.0M+10.1%	$88.1M+46.8%	$60.0M+25.9%	$47.6M+7.8%	$44.2M+62.7%	$27.2M-62.4%	$72.2M-13.6%	$83.6M-34.2%	$127.1M+32.6%	$95.8M+52.9%	$62.7M
Cash & Equivalents	$82.9M-18.4%	$101.7M-33.7%	$153.3M+165.1%	$57.8M-38.0%	$93.3M+8.1%	$86.4M+52.3%	$56.7M+23.8%	$45.8M+5.3%	$43.5M+68.9%	$25.7M-60.9%	$65.8M-16.2%	$78.4M-22.8%	$101.7M+124.2%	$45.3M-6.2%	$48.3M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$496K	$0-100.0%	$20.0M-50.0%	$40.0M	$0
Accounts Receivable	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A	$474K-87.3%	$3.7M+24.2%	$3.0M-19.8%	$3.7M-50.1%	$7.5M-36.7%	$11.8M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$168.7M+21.1%	$139.4M-4.3%	$145.6M+789.4%	$16.4M-33.7%	$24.7M-36.5%	$38.9M-24.9%	$51.7M+15.0%	$45.0M+14.9%	$39.1M-48.4%	$75.9M-1.7%	$77.2M-10.6%	$86.3M-37.8%	$138.8M+64.8%	$84.2M+33.6%	$63.0M
Current Liabilities	$34.8M+42.9%	$24.4M+25.0%	$19.5M+186.0%	$6.8M-47.4%	$13.0M+5.4%	$12.3M+38.6%	$8.9M+55.6%	$5.7M-23.2%	$7.4M-77.2%	$32.5M+39.5%	$23.3M-35.7%	$36.2M+22.3%	$29.6M+24.4%	$23.8M+15.5%	$20.6M
Non-Current Liabilities	$133.9M+16.5%	$115.0M-8.8%	$126.1M+1220.2%	$9.6M-18.5%	$11.7M-55.9%	$26.6M-38.0%	$42.9M+9.1%	$39.3M+23.9%	$31.7M-26.9%	$43.4M-19.5%	$53.9M+7.7%	$50.1M-54.1%	$109.1M+80.7%	$60.4M+42.4%	$42.4M
Long-Term Debt	$96.5M-9.8%	$106.9M-9.8%	$118.5M	$0	N/A	$12.8M-52.9%	$27.1M+24.9%	$21.7M+48.8%	$14.6M-42.4%	$25.3M-40.8%	$42.8M+162.5%	$16.3M-53.7%	$35.1M-6.6%	$37.7M+12.3%	$33.5M
Total Equity	$83.9M+35.6%	$61.9M-30.2%	$88.7M-28.5%	$124.0M-12.6%	$141.9M+64.2%	$86.4M+96.5%	$44.0M+134.2%	$18.8M+224.7%	$5.8M+112.3%	-$47.2M-1944.6%	-$2.3M-174.5%	$3.1M+177.7%	-$4.0M-118.6%	$21.5M+43.0%	$15.0M
Retained Earnings	-$1.2B+1.3%	-$1.2B-1.1%	-$1.2B-3.5%	-$1.2B-1.5%	-$1.2B+1.3%	-$1.2B+1.1%	-$1.2B-0.2%	-$1.2B-1.1%	-$1.2B+1.2%	-$1.2B-4.7%	-$1.1B-1.8%	-$1.1B-3.5%	-$1.1B-13.0%	-$957.1M-8.0%	-$886.1M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$271.9M+27.8%	$272.7M+23.2%	$263.2M+17.8%	$223.5M-8.1%	$212.8M-3.0%	$221.3M-5.6%	$223.3M+80.0%	$243.3M+93.6%
Current Assets	$118.7M+4.9%	$117.3M-6.6%	$110.7M-30.4%	$104.9M-35.3%	$113.2M-22.9%	$125.6M-25.8%	$159.0M+360.9%	$162.2M+322.2%
Cash & Equivalents	$85.6M-5.2%	$82.9M-18.4%	$45.2M-68.2%	$75.1M-47.8%	$90.3M-33.7%	$101.7M-33.7%	$142.1M+324.4%	$143.9M+357.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$159.0M+24.1%	$168.7M+21.1%	$155.2M+12.0%	$131.0M-8.6%	$128.1M-6.5%	$139.4M-4.3%	$138.5M+664.1%	$143.3M+822.2%
Current Liabilities	$33.1M+61.9%	$34.8M+42.9%	$28.3M+33.9%	$21.5M+15.5%	$20.4M+31.5%	$24.4M+25.0%	$21.1M+104.5%	$18.6M+162.7%
Non-Current Liabilities	$125.9M+16.9%	$133.9M+16.5%	$126.9M+8.1%	$109.5M-12.2%	$107.7M-11.4%	$115.0M-8.8%	$117.4M+1405.9%	$124.7M+1375.4%
Long-Term Debt	$88.8M-11.1%	$96.5M-9.8%	$94.4M-12.7%	$102.2M-11.2%	$99.9M-12.7%	$106.9M-9.8%	$108.1M	$115.1M
Total Equity	$92.9M+9.7%	$83.9M+35.6%	$87.9M+3.7%	$72.4M-27.6%	$84.6M+2.8%	$61.9M-30.2%	$84.8M-20.0%	$100.0M-9.2%
Retained Earnings	-$1.2B+1.5%	-$1.2B+1.3%	-$1.2B+1.6%	-$1.2B-1.0%	-$1.2B-0.3%	-$1.2B-1.1%	-$1.2B-2.5%	-$1.2B-1.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

XOMA Cash Flow Statement

XOMA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$6.8M	$2.9M+120.9%	-$13.7M+24.3%	-$18.2M-41.0%	-$12.9M-156.8%	$22.7M+124.7%	$10.1M+3641.1%	-$285K+97.7%	-$12.6M-570.7%	$2.7M+108.0%	-$33.7M-9.1%	-$30.9M+60.5%	-$78.3M-70.5%	-$45.9M-12.6%	-$40.8M-40.3%	-$29.1M
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	$22K-12.0%	$25K-16.7%	$30K-90.0%	$300K-62.5%	$800K-46.7%	$1.5M-21.1%	$1.9M-34.5%	$2.9M-29.3%	$4.1M-23.5%	$5.4M
Stock-Based Compensation	N/A	$9.3M-10.1%	$10.3M+13.3%	$9.1M+152.2%	$3.6M-41.8%	$6.2M+56.4%	$4.0M-19.9%	$4.9M+26.8%	$3.9M-46.6%	$7.3M-4.5%	$7.6M-21.4%	$9.7M-9.7%	$10.8M+111.3%	$5.1M+19.0%	$4.3M-44.8%	$7.8M
Capital Expenditures	N/A	N/A	$20K+17.6%	$17K-99.9%	$15.2M	N/A	$9K	N/A	$6K-25.0%	$8K-86.4%	$59K-86.3%	$430K+32.3%	$325K-72.2%	$1.2M-53.4%	$2.5M-24.1%	$3.3M
Free Cash Flow	N/A	N/A	-$13.8M+24.2%	-$18.2M+35.4%	-$28.1M	N/A	$10.1M	N/A	-$12.7M-572.4%	$2.7M+107.9%	-$33.7M-7.7%	-$31.3M+60.2%	-$78.6M-67.0%	-$47.1M-8.8%	-$43.3M-33.7%	-$32.4M
Investing Cash Flow	$64.1M	$50.9M+280.1%	-$28.3M-3874.5%	-$711K+96.5%	-$20.2M+23.7%	-$26.5M-12579.4%	-$209K+98.9%	-$19.3M-28.6%	-$15.0M-1034.4%	$1.6M	N/A	N/A	N/A	$18.8M+144.8%	-$42.0M-1171.7%	-$3.3M
Financing Cash Flow	-$27.2M	-$26.5M-137.8%	-$11.1M-109.2%	$120.6M+2809.3%	-$4.5M-134.7%	$12.8M-35.2%	$19.8M-35.1%	$30.5M+1.9%	$29.9M+125.8%	$13.3M	N/A	N/A	N/A	$83.4M+4.5%	$79.8M+81.4%	$44.0M
Dividends Paid	$5.5M	$5.5M0.0%	$5.5M0.0%	$5.5M0.0%	$5.5M+56.4%	$3.5M	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$15.8M	$16.0M+123307.7%	$13K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	$6.1M+178.5%	-$5.5M-89.5%	-$296K+96.6%	$6.5M+137.3%	$2.2M+144.4%	-$2.9M+26.1%	-$8.6M-310.9%	$2.7M+137.8%
Stock-Based Compensation	$2.3M+15.0%	N/A	N/A	N/A	$2.0M-30.6%	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$3K	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$2.9M	-$8.6M	$2.7M
Investing Cash Flow	$6.6M+197.9%	$19.3M+153.1%	$58.2M+511.4%	-$20.0M-438.9%	-$6.7M+7.6%	-$36.4M-761.1%	$9.5M+73.3%	$5.9M+231.5%
Financing Cash Flow	-$7.6M-10.8%	-$10.7M-902.7%	-$5.8M-46.2%	-$3.0M-174.5%	-$6.9M-39.1%	-$1.1M-100.9%	-$4.0M-192.5%	-$1.1M+5.2%
Dividends Paid	$1.4M+4.1%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%
Share Buybacks	$264K-51.6%	$13.6M	$25K	$1.8M	$545K+4092.3%	$0	$0	$0

Not reported in any period shown, so not listed: Depreciation & Amortization.

XOMA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

XOMA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	99.6%-0.4pp	100.0%
Operating Margin	21.8%	-140.3%	-879.5%	-288.9%	45.9%+3.7pp	42.3%+63.4pp	-21.1%	-318.1%	32.3%	-1106.4%	-71.6%	-433.8%	-164.2%	-167.6%	-58.4%
Net Margin	60.8%+109.3pp	-48.5%	-858.1%	-283.8%	41.4%-3.9pp	45.3%+56.0pp	-10.8%	-251.8%	27.7%	-962.1%	-37.2%	-203.0%	-349.9%	-210.4%	-56.3%
Return on Equity	37.8%+60.1pp	-22.3%+23.7pp	-46.0%-32.2pp	-13.8%-24.9pp	11.1%-4.3pp	15.4%+19.9pp	-4.5%+66.5pp	-71.0%-323.3pp	252.3%	N/A	N/A	-1235.9%	N/A	-331.0%-112.9pp	-218.1%
Return on Assets	11.6%+17.9pp	-6.3%+11.2pp	-17.4%-5.3pp	-12.2%-21.7pp	9.5%-1.1pp	10.6%+12.7pp	-2.1%+18.9pp	-20.9%-53.4pp	32.5%+219.2pp	-186.7%-159.1pp	-27.5%+15.3pp	-42.8%+49.2pp	-92.0%-24.8pp	-67.3%-25.3pp	-42.0%
Current Ratio	3.37-1.8x	5.15-3.5x	8.68-0.3x	8.98+1.5x	7.48+0.3x	7.16+0.4x	6.76-1.6x	8.35+2.4x	5.95+5.1x	0.84-2.3x	3.10+0.8x	2.31-2.0x	4.29+0.3x	4.02+1.0x	3.04
Debt-to-Equity	1.15-0.6x	1.73+0.4x	1.34+1.3x	0.00-0.2x	0.170.0x	0.15-0.5x	0.62-0.5x	1.15-1.4x	2.52	N/A	N/A	5.26	N/A	1.75-0.5x	2.23
Asset Turnover	0.19+0.1x	0.13+0.1x	0.020.0x	0.04-0.2x	0.230.0x	0.230.0x	0.19+0.1x	0.08-1.1x	1.17+1.0x	0.19-0.5x	0.74+0.5x	0.21-0.1x	0.26-0.1x	0.32-0.4x	0.75
FCF Margin	N/A	-48.3%	-382.0%	-466.7%	N/A	34.3%	N/A	-238.7%	5.1%	-606.5%	-56.5%	-416.7%	-132.8%	-128.1%	-55.6%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Margin	-3.9%-41.2pp	15.9%+99.1pp	-14.2%	35.1%+126.0pp	37.3%	-83.2%	-217.3%	-90.9%
Net Margin	36.3%+21.4pp	44.4%+89.9pp	150.3%	70.0%	14.9%	-45.5%	-239.6%	144.2%
Return on Equity	4.8%+2.0pp	7.3%+13.7pp	16.0%+36.3pp	12.7%-3.3pp	2.8%+13.2pp	-6.4%+16.3pp	-20.3%-15.1pp	16.0%+20.9pp
Return on Assets	1.6%+0.5pp	2.2%+4.0pp	5.3%+13.1pp	4.1%-2.5pp	1.1%+5.0pp	-1.8%+6.8pp	-7.7%-3.3pp	6.6%+10.9pp
Current Ratio	3.59-2.0x	3.37-1.8x	3.91-3.6x	4.88-3.8x	5.54-3.9x	5.15-3.5x	7.52+4.2x	8.71+3.3x
Debt-to-Equity	0.96-0.2x	1.15-0.6x	1.07-0.2x	1.41+0.3x	1.18-0.2x	1.73+0.4x	1.27+1.1x	1.15+1.0x
Asset Turnover	0.050.0x	0.050.0x	0.040.0x	0.060.0x	0.07+0.1x	0.040.0x	0.030.0x	0.050.0x
FCF Margin	N/A	N/A	N/A	N/A	N/A	-33.4%	-119.8%	24.6%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
XOMA Royalty Corporation XOMA	FY2025	$52.1M	$31.7M	60.8%	$710.2M	67/100
Astria Therapeutics, Inc. ATXS	FY2024	N/A	-$94.3M	N/A	$718.1M	—
Erasca, Inc. ERAS	FY2025	N/A	-$124.5M	N/A	$5.2B	—
Prothena Corporation plc PRTA	FY2025	$9.7M	-$244.1M	N/A	$429.2M	55/100
Zevra Therapeutics, Inc. ZVRA	FY2025	$106.5M	$83.2M	78.2%	$617.0M	52/100
Arcturus Therapeutics Holdings Inc. ARCT	FY2025	$82.0M	-$65.8M	-80.2%	$341.9M	54/100

Where XOMA Royalty Corporation Ranks

Frequently Asked Questions

What is XOMA Royalty Corporation's annual revenue?

XOMA Royalty Corporation (XOMA) reported $52.1M in total revenue for fiscal year 2025. This represents a 83.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is XOMA Royalty Corporation's revenue growing?

XOMA Royalty Corporation (XOMA) revenue grew by 83.1% year-over-year, from $28.5M to $52.1M in fiscal year 2025.

Is XOMA Royalty Corporation profitable?

Yes, XOMA Royalty Corporation (XOMA) reported a net income of $31.7M in fiscal year 2025, with a net profit margin of 60.8%.

How much debt does XOMA Royalty Corporation have?

As of fiscal year 2025, XOMA Royalty Corporation (XOMA) had $82.9M in cash and equivalents against $96.5M in long-term debt.

What is XOMA Royalty Corporation's operating margin?

XOMA Royalty Corporation (XOMA) had an operating margin of 21.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is XOMA Royalty Corporation's net profit margin?

XOMA Royalty Corporation (XOMA) had a net profit margin of 60.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is XOMA Royalty Corporation's return on equity (ROE)?

XOMA Royalty Corporation (XOMA) has a return on equity of 37.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is XOMA Royalty Corporation's operating cash flow?

XOMA Royalty Corporation (XOMA) generated $2.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are XOMA Royalty Corporation's total assets?

XOMA Royalty Corporation (XOMA) had $272.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does XOMA Royalty Corporation spend on research and development?

XOMA Royalty Corporation (XOMA) invested $1.7M in research and development during fiscal year 2025.

Does XOMA Royalty Corporation buy back shares?

Yes, XOMA Royalty Corporation (XOMA) spent $16.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does XOMA Royalty Corporation have outstanding?

XOMA Royalty Corporation (XOMA) had 12M shares outstanding as of fiscal year 2025.

What is XOMA Royalty Corporation's current ratio?

XOMA Royalty Corporation (XOMA) had a current ratio of 3.37 as of fiscal year 2025, which is generally considered healthy.

What is XOMA Royalty Corporation's debt-to-equity ratio?

XOMA Royalty Corporation (XOMA) had a debt-to-equity ratio of 1.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is XOMA Royalty Corporation's return on assets (ROA)?

XOMA Royalty Corporation (XOMA) had a return on assets of 11.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is XOMA Royalty Corporation's Altman Z-Score?

XOMA Royalty Corporation (XOMA) has an Altman Z-Score of -3.05, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is XOMA Royalty Corporation's Piotroski F-Score?

XOMA Royalty Corporation (XOMA) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are XOMA Royalty Corporation's earnings high quality?

XOMA Royalty Corporation (XOMA) has an earnings quality ratio of 0.09x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can XOMA Royalty Corporation cover its interest payments?

XOMA Royalty Corporation (XOMA) has an interest coverage ratio of 0.87x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is XOMA Royalty Corporation?

XOMA Royalty Corporation (XOMA) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.